Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies
Version 4 2024-10-22, 05:00Version 4 2024-10-22, 05:00
Version 3 2024-06-19, 05:20Version 3 2024-06-19, 05:20
Version 2 2024-06-04, 15:53Version 2 2024-06-04, 15:53
Version 1 2021-09-28, 12:58Version 1 2021-09-28, 12:58
journal contribution
posted on 2024-10-22, 05:00authored byRN Martins, V Villemagne, HR Sohrabi, P Chatterjee, TM Shah, G Verdile, P Fraser, K Taddei, Veer GuptaVeer Gupta, SR Rainey-Smith, E Hone, S Pedrini, WL Lim, I Martins, S Frost, S Gupta, S O'Bryant, A Rembach, D Ames, K Ellis, SJ Fuller, B Brown, SL Gardener, B Fernando, P Bharadwaj, S Burnham, SM Laws, AM Barron, K Goozee, EJ Wahjoepramono, PR Asih, JD Doecke, O Salvado, AI Bush, CC Rowe, SE Gandy, CL Masters
Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies